Van ECK Associates Corp Acquires 267 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Van ECK Associates Corp grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 56.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 740 shares of the company’s stock after purchasing an additional 267 shares during the quarter. Van ECK Associates Corp’s holdings in Twist Bioscience were worth $34,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $34,000. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $95,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after buying an additional 1,226 shares during the last quarter.

Twist Bioscience Stock Down 0.3 %

TWST stock opened at $41.20 on Tuesday. The firm’s fifty day simple moving average is $47.95 and its 200-day simple moving average is $45.73. The company has a market capitalization of $2.46 billion, a P/E ratio of -12.19 and a beta of 1.87. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.75) EPS. As a group, equities research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity

In related news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the transaction, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Paula Green sold 860 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the transaction, the senior vice president now owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. This represents a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,180 shares of company stock valued at $1,821,971 in the last ninety days. Insiders own 3.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TWST shares. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. TD Cowen reissued a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Finally, Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and an average price target of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.